Topical estradiol does not interfere with the expression of the metalloproteinase-1 enzyme in photo exposed skin cells / Estradiol tópico não interfere na expressão da enzima metaloproteinase-1 em células da pele fotoexposta

BACKGROUND: In postmenopausal women there is a rapid destruction of dermal collagen, resulting in accelerated skin ageing, which is manifested by cutaneous atrophy, increased number and depth of wrinkles and sagging. This accelerated catabolism of the collagen is due to estrogen deficiency and increased synthesis of the metalloproteinase-1 enzyme, which degrades the dermal collagen. OBJECTIVES: To assess whether the use of topical estradiol 0.05% cream on photo exposed skin can inhibit the expression of the metalloproteinase-1 enzyme on the dermis and subsequently the rapid loss of collagen in women after menopause. METHODS: We included 40 postmenopausal women without hormone replacement therapy. Information about lifestyle, lipid profile, blood glucose level, thyroid hormones, mammography, Pap smear and transvaginal ultrasound were obtained to rule out associated diseases. Skin biopsy of the right preauricular region was performed before and after treatment with topical estradiol 0.05% for 30 days. The biopsy specimens were subjected to immunohistochemistry to identify the expression of the metalloproteinase-1 enzyme. RESULTS: There was no statistically significant difference on the expression of the metalloproteinase-1 enzyme in keratinocytes, fibroblasts and endothelial cells before and after treatment with topical estradiol for 30 days. CONCLUSION: Treatment with estradiol 0.05% cream, in photo exposed skin for 30 days, does not inhibit the production of metalloproteinase-1.

FUNDAMENTOS: Na pós-menopausa, ocorre rápida destruição do colágeno dérmico, com consequente envelhecimento acelerado da pele, que se expressa com atrofia cutânea, aumento do número e da profundidade das rugas e flacidez. Esse catabolismo acelerado do colágeno ocorre por deficiência estrogênica e aumento na síntese da enzima metaloproteinase-1, que degrada o colágeno dérmico. OBJETIVOS: Avaliar se o uso de estradiol tópico a 0,05% em creme na pele fotoexposta pode inibir a expressão da enzima metaloproteinase-1 na derme e, consequentemente, a perda acelerada do colágeno em mulheres na pósmenopausa. MÉTODOS: Foram incluídas 40 mulheres na pós-menopausa sem terapia de reposição hormonal. Informações sobre hábitos de vida, perfil lipídico, níveis glicêmicos, hormônios tireoidianos, mamografia, colpocitologia oncótica e ultrassom transvaginal foram obtidas para excluir doenças associadas. Biópsia de pele da região pré-auricular direita foi realizada antes e após tratamento com estradiol tópico a 0,05% por 30 dias. Os espécimes de biópsia foram submetidos à reação imunoistoquímica para identificar a expressão da enzima metaloproteinase-1. RESULTADOS: Não foi observada diferença estatisticamente significativa na expressão da enzima metaloproteinase-1 em queratinócitos, células endoteliais e fibroblastos da pele antes e após tratamento com estradiol tópico por 30 dias. CONCLUSÃO: O tratamento com creme contendo estradiol a 0,05% em pele fotoexposta por 30 dias não inibe a produção da enzima metaloproteinase-1.

Cordycepin inhibits UVB-induced matrix metalloproteinase expression by suppressing the NF-kappa B pathway in human dermal fibroblasts

Cordycepin (3'-deoxyadenosine) has been shown to exhibit many pharmacological activities, including anti-cancer, anti-inflammatory, and anti-infection activities. However, the anti-skin photoaging effects of cordycepin have not yet been reported. In the present study, we investigated the inhibitory effects of cordycepin on matrix metalloproteinase-1 (MMP-1) and -3 expressions of the human dermal fibroblast cells. Western blot analysis and real-time PCR revealed cordycepin inhibited UVB-induced MMP-1 and -3 expressions in a dose-dependent manner. UVB strongly activated NF-kappa B activity, which was determined by I kappa B alpha degradation, nuclear localization of p50 and p65 subunit, and NF-kappa B binding activity. However, UVB-induced NF-kappa B activation and MMP expression were completely blocked by cordycepin pretreatment. These findings suggest that cordycepin could prevent UVB-induced MMPs expressions through inhibition of NF-kappa B activation. In conclusion, cordycepin might be used as a potential agent for the prevention and treatment of skin photoaging.